Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendoza, S. A.
Right arrow Articles by Tune, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendoza, S. A.
Right arrow Articles by Tune, B. M.

Journal of the American Society of Nephrology, Vol 3, 889-894, Copyright © 1992 by American Society of Nephrology

EDITORIALS

Treatment of childhood nephrotic syndrome

SA Mendoza and BM Tune

This review examines selected aspects of the treatment of the nephrotic syndrome in children. Particular attention has been paid to two groups of nephrotic children. First, children with steroid-responsive nephrotic syndrome are discussed. Recently, a series of controlled studies have provided important information regarding the optimal duration of steroid therapy. Initial episodes of the nephrotic syndrome are best treated with "long" courses of prednisone therapy (6 wk of high-dose daily prednisone followed by 6 wk of alternate-day prednisone). In contrast, relapses do as well with "short" courses (about 2 wk of daily prednisone and 2 wk of alternate-day therapy). Some children who are steroid responsive require high doses of prednisone to remain in remission. These patients may require alkylating agent therapy. The most common cause of steroid-resistant nephrotic syndrome is focal segmental glomerulosclerosis. Over the past 10 yr, these patients have been treated with an intensive protocol involving multiple infusions of high-dose methylprednisolone and, in many cases, oral alkylating agent therapy. Current experience with this treatment is presented. The protocol appears to improve the outcome in children with focal segmental glomerulosclerosis, although it is believed that it is essential that these observations be confirmed by a controlled trial. There is also interest in the use of angiotensin- converting enzyme inhibitors and cyclosporine in the treatment of childhood nephrotic syndrome. The experience with these agents is briefly reviewed, but the current data are inadequate to indicate their role(s) in this condition.


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
M. P. Winn, N. Daskalakis, R. F. Spurney, and J. P. Middleton
Unexpected Role of TRPC6 Channel in Familial Nephrotic Syndrome: Does It Have Clinical Implications?
J. Am. Soc. Nephrol., February 1, 2006; 17(2): 378 - 387.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Carreno, E. Morales, B. Dominguez-Gil, J. C. Herrero, M. Ortiz, E. Gonzalez, and M. Praga
The patient with over 100 relapses of minimal change nephrotic syndrome: prolonged complete remission after chlorambucil treatment
Nephrol. Dial. Transplant., June 1, 2000; 15(6): 922 - 923.
[Full Text] [PDF]

Home page
 NEJMHome page
V. J. Savin, R. Sharma, M. Sharma, E. T. McCarthy, S. K. Swan, E. Ellis, H. Lovell, B. Warady, S. Gunwar, A. M. Chonko, et al.
Circulating Factor Associated with Increased Glomerular Permeability to Albumin in Recurrent Focal Segmental Glomerulosclerosis
N. Engl. J. Med., April 4, 1996; 334(14): 878 - 883.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673